What this trial studies
The investigators are assessing how seasonal changes affect kidney function biomarkers in post-menopausal women, an understudied group. While heat stress can reduce kidney function, previous research has not accounted for physical activity, diet, hydration, or sun exposure.
Conditions in scope
- Postmenopausal
- Female
Interventions
- There will be no intervention. (Other) — This research focuses on examining seasonal variations in kidney function among postmenopausal females. As an observational study, our approach is non-interventional.
Who can join
Women only · Ages 55 Years and up
Inclusion criteria
- Female aged ≥55 years old
- Self Reported as at least one year post-menopause
- Live in Tallahassee, Florida, or the surrounding area
Exclusion criteria
- Have a BMI of ≥30 kg/m2
- Systolic blood pressure of ≥140 and/or diastolic blood pressure ≥90 mmHg
- Self Reported Current or recent (regular use within the past six months) use of a diuretic medication
- Self Reported: Uncontrolled cardiovascular, respiratory, neurological, renal, liver, or metabolic health condition
- Current or recent (regular use within the past six months) use of tobacco, nicotine, nonsteroidal anti-inflammatory products
- No regular (≥once per week) purposeful heat exposure (e.g., sauna, spa, etc.)
Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.
Where it’s happening
| City | State / Region | Facility | Site status |
|---|---|---|---|
| Tallahassee | Florida | Florida State University | Unknown |
Status & timeline
- Overall status: Completed
- Study type: Observational
- Phase: N/A
- Start date: 2025-01-03
- Primary completion: 2025-09-03
- Last update posted: 2025-10-06
- First posted: 2025-03-10
Sponsor & contact
Lead sponsor: Florida State University (Other)
For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.
Outcome measures
Primary outcomes
- Plasma neutrophil gelatinase-associated lipocalin (NGAL) (Visit 1 (0 months) and Visit 2 (7 months))
Changes in NGAL will be measured in blood samples using enzyme-linked immunosorbent assay. - Urinary neutrophil gelatinase-associated lipocalin (NGAL) (Visit 1 (0 months) and Visit 2 (7 months))
Changes in NGAL will be measured in urine samples using radioimmunoassay. - Insulin-like growth factor-binding protein 7 (IGFBP7)*Tissue inhibitor of metalloproteinase-2 (TIMP-2) (Visit 1 (0 months) and Visit 2 (7 months))
The product of Insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinase-2 (TIMP-2) will be measured in blood samples using enzyme-linked immunosorbent assays.
Related ClearedRx care
If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.
Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT06866743 before contacting a site.
ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.